Analysts Issue Forecasts for Bone Biologics FY2026 Earnings

Bone Biologics Corp. (NASDAQ:BBLG) – Investment analysts at Zacks Research cut their FY2026 earnings estimates for Bone Biologics in a report issued on Tuesday, March 3rd. Zacks Research analyst B. Sorensen now expects that the company will post earnings of ($1.93) per share for the year, down from their previous forecast of ($1.36). The consensus estimate for Bone Biologics’ current full-year earnings is ($5.00) per share.

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Bone Biologics in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Bone Biologics Trading Up 4.9%

Shares of BBLG opened at $1.28 on Thursday. The stock’s 50-day moving average price is $1.45 and its two-hundred day moving average price is $1.86. Bone Biologics has a 12 month low of $1.11 and a 12 month high of $6.75. The company has a market capitalization of $2.30 million, a PE ratio of -0.34 and a beta of 0.78.

Institutional Trading of Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC grew its holdings in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the period. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. 34.30% of the stock is owned by hedge funds and other institutional investors.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.